{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:50:58Z","timestamp":1791337858208,"version":"4.3.1"},"reference-count":23,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2016,11,3]],"date-time":"2016-11-03T00:00:00Z","timestamp":1478131200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Sleep Research"],"published-print":{"date-parts":[[2017,8]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>This <jats:italic>post hoc<\/jats:italic> analysis evaluated the dose\u2010related effects of sodium oxybate on sleep continuity and nocturnal sleep quality in patients with narcolepsy\u2013cataplexy. Polysomnography data, including shifts to Stage N1\/Wake, were from a randomized, placebo\u2010controlled trial of sodium oxybate. Patients were \u226516\u00a0years old with a diagnosis of narcolepsy including symptoms of cataplexy and excessive daytime sleepiness. Treatment was for 8\u00a0weeks with placebo or sodium oxybate 4.5, 6 or 9\u00a0g administered as two equally divided nightly doses. Relative to baseline, significant dose\u2010dependent reductions in the number of shifts per hour from Stages N2\/3\/rapid eye movement and Stages N2\/3 to Stage N1\/Wake were observed at week 8 with sodium oxybate (<jats:italic>P\u00a0<\/jats:italic>&lt;\u00a00.05); sodium oxybate 6\u2010 and 9\u2010g doses also resulted in similar reductions in shifts per hour of rapid eye movement to Stage N1\/Wake (both <jats:italic>P\u00a0<\/jats:italic>&lt;\u00a00.05). Across all shift categories, the shift reductions with sodium oxybate 9\u00a0g were significantly greater than those observed with placebo (<jats:italic>P\u00a0<\/jats:italic>&lt;\u00a00.05). Improvements from baseline in reported sleep quality were significantly greater with sodium oxybate 4.5 and 9\u00a0g at week 8 (<jats:italic>P\u00a0<\/jats:italic>&lt;\u00a00.05). Correlations between change from baseline in number of shifts per hour to Stage N1\/Wake and cataplexy frequency, patient\u2010reported nocturnal sleep quality, and excessive daytime sleepiness assessed using the Epworth Sleepiness Scale were numerically highest for the sodium oxybate 9\u2010g dose across all sleep stage shift categories. In these patients with narcolepsy, sodium oxybate showed improvements in the sleep continuity and nocturnal sleep quality that are characteristic of disrupted nighttime sleep (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link> identifier <jats:styled-content style=\"fixed-case\">NCT<\/jats:styled-content>00049803).<\/jats:p>","DOI":"10.1111\/jsr.12468","type":"journal-article","created":{"date-parts":[[2016,11,3]],"date-time":"2016-11-03T06:43:19Z","timestamp":1478155399000},"page":"407-414","source":"Crossref","is-referenced-by-count":60,"title":["Effect of sodium oxybate on disrupted nighttime sleep in patients with narcolepsy"],"prefix":"10.1111","volume":"26","author":[{"given":"Thomas","family":"Roth","sequence":"first","affiliation":[{"name":"Henry Ford Hospital Detroit MI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Dauvilliers","sequence":"additional","affiliation":[{"name":"National Reference Network for Narcolepsy Sleep Disorder Center Gui de Chauliac hospital CHU Montpellier INSERM, U1061 Montpellier France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Guinta","sequence":"additional","affiliation":[{"name":"Jazz Pharmaceuticals Palo Alto CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Alvarez\u2010Horine","sequence":"additional","affiliation":[{"name":"Jazz Pharmaceuticals Palo Alto CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efim","family":"Dynin","sequence":"additional","affiliation":[{"name":"Jazz Pharmaceuticals Palo Alto CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jed","family":"Black","sequence":"additional","affiliation":[{"name":"Jazz Pharmaceuticals Palo Alto CA USA"},{"name":"Stanford Center for Sleep Research and Medicine Redwood City CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,11,3]]},"reference":[{"key":"e_1_2_9_2_1","volume-title":"The International Classification of Sleep Disorders \u2013 Third Edition (ICSD\u20103)","author":"American Academy of Sleep Medicine","year":"2014"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.27994"},{"key":"e_1_2_9_4_1","doi-asserted-by":"crossref","first-page":"427","DOI":"10.5664\/jcsm.4598","article-title":"Time to response with sodium oxybate for the treatment of excessive daytime sleepiness (EDS) and cataplexy in patients with narcolepsy","volume":"11","author":"Bogan R. K.","year":"2015","journal-title":"J. Clin. Sleep Med."},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2011.09.001"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0317167100119304"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2015.06.007"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60237-2"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2014.97"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/14.6.540"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/16.3.216"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/13.1.24"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(73)90839-8"},{"key":"e_1_2_9_14_1","first-page":"273","article-title":"The effects of gamma\u2010hydroxybutyrate on sleep","volume":"12","author":"Mamelak M.","year":"1977","journal-title":"Biol. Psychiatry"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.65.10.1337"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.5665\/sleep.4908"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.3004"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.5665\/sleep.2880"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.5665\/sleep.1992"},{"key":"e_1_2_9_20_1","unstructured":"Xyrem (Sodium Oxybate) 500 mg\/mL Oral Solution.European Union Summary of Product Characteristics.UCB Pharma Berkshire UK October 2010."},{"key":"e_1_2_9_21_1","unstructured":"Xyrem (Sodium Oxybate) Oral Solution.Canadian Product Monograph.Valeant Canada September2009."},{"key":"e_1_2_9_22_1","unstructured":"Xyrem\u00ae(Sodium Oxybate) Oral Solution.US Prescribing Information.Jazz Pharmaceuticals Palo Alto CA April2015."},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.26368"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2005.03.010"}],"container-title":["Journal of Sleep Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjsr.12468","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjsr.12468","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jsr.12468","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T12:47:17Z","timestamp":1696164437000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jsr.12468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,3]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["10.1111\/jsr.12468"],"URL":"https:\/\/doi.org\/10.1111\/jsr.12468","archive":["Portico"],"relation":{},"ISSN":["0962-1105","1365-2869"],"issn-type":[{"value":"0962-1105","type":"print"},{"value":"1365-2869","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,3]]}}}